Genzyme Reports More Good News For Mozobil
This article was originally published in The Pink Sheet Daily
Executive Summary
Second Phase III trial shows twice the stem cell mobilization power called for in multiple myeloma protocol, adding to high efficacy shown in lymphoma study reported in July.
You may also be interested in...
Genzyme’s Synvisc-ONE and Myozyme Could Both See Delays After Advisory Committees
A Dec. 9 advisory committee meeting for the osteoarthritis pain management candidate leaves two weeks for FDA turnaround by the product’s action date.
Genzyme’s Synvisc-ONE and Myozyme Could Both See Delays After Advisory Committees
A Dec. 9 advisory committee meeting for the osteoarthritis pain management candidate leaves two weeks for FDA turnaround by the product’s action date.
Genzyme’s Synvisc-ONE and Myozyme Could Both See Delays After Advisory Committees
A Dec. 9 advisory committee meeting for the osteoarthritis pain management candidate leaves two weeks for FDA turnaround by the product’s action date.